chenodeoxycholic acid
Trade name: Chenix
Small moleculeapproved
Approved
Jul 28, 1983
Chenodeoxycholic acid is a bile acid. Salts of this carboxylic acid are called chenodeoxycholates. Chenodeoxycholic acid is one of the main bile acids. It was first isolated from the bile of the domestic goose, which gives it the "cheno" portion of its name. — Wikipedia
Clinical trial activity
16 trials · 15 clinical orgs · 5 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
1
Phase 4
6
Earliest trial started Jan 1, 1996 (NCT00004346)
Timeline
1980s
- Jul 28, 1983
Earliest FDA Approval
- Jul 28, 1983
Leadiant Biosciences, Inc. — NDA Secondary Org
1990s
- Jan 1, 1996
Earliest Phase 2 Sponsor(trial)
2000s
- Jan 1, 2004
Earliest Phase 1 Sponsor(trial)
- Oct 22, 2009
LGM Pharma — Marketing Organization
- Oct 22, 2009
Nexgen Pharma, Inc — Marketing Organization
2020s
- Jan 1, 2024
Leadiant Biosciences, Inc. — Earliest Phase 3 Sponsor(trial)
- Feb 21, 2025
Mirum Pharmaceuticals, Inc. — Marketing Organization
Indications
Approved for
Studied for
- Bile Acids and Salts · Phase 4
- Cholelithiasis · Phase 4
- Constipation · Phase 2
- Echolocation · Phase 1
- Hyperlipidemia, Familial Combined · Early Phase 1
- Hyperlipoproteinemia Type IV · Early Phase 1
- Metabolic Syndrome · Early Phase 1
- Obesity, Morbid · Phase 4
- Spastic Paraplegia, Hereditary · Phase 2
- Xanthomatosis, Cerebrotendinous · Phase 2
Mechanism of action
- Bile acid receptor FXRAGONIST
NR1H4 agonist
Approval history
- approvedPriority reviewJul 28, 1983
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C- Mol. weight
- 392.58 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Black box warning
Sources
- WikipediaChenodeoxycholic acid ↗
- ChEMBLCHEMBL240597 ↗
Also known as
- 3alpha,7alpha-dihydroxy-5beta-cholanic acid
- 3alpha,7alpha-dihydroxy-5beta-cholanic acid
- 7alpha-hydroxylithocholic acid
- 7alpha-hydroxylithocholic acid
- anthropodeoxycholic acid
- anthropodeoxycholic acid
- anthropodesoxycholic acid
- anthropodesoxycholic acid
- anthropodesoxycholic acid
- anthropododesoxycholic acid
- cdca
- cdca
- chendol 125
- chendol 250
- chenic acid
- chenic acid
- chenic acid
- chenic acid
- chenix
- chenix
- chenix
- chenocedon
- chenocedon
- chenocholic acid
- chenocholic acid
- chenodeoxycholate
- chenodeoxycholate
- chenodeoxycholic acid
- chenodeoxycholic acid
- chenodeoxycholic acid
- chenodeoxycholic acid
- chenodeoxycholic acid
- chenodeoxycholic acid
- chenodeoxycholic acid
- chenodesoxycholic acid
- chenodesoxycholic acid
- chenodesoxycholic acid
- chenodiol
- chenodiol
- chenodiol
- chenodiol
- chenodiol
- chenodiol
- chenodiol
- chenodiol
- chenodiol
- chenofalk
- chenofalk
- combidol
- gallodesoxycholic acid
- gallodesoxycholic acid
- gallodesoxycholic acid
- lithofalk
- sodium chenodeoxycholate
- sodium chenodeoxycholate
- xenbilox
- xenbilox
- xenbilox
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07005752 | Phase 4 | Jul 28, 2025 | Myungmoon Pharm. Co. |
| NCT06260748 | Phase 3 | May 27, 2024 | Leadiant Biosciences, Inc. |
| NCT06180057 | Phase 1 | Jun 12, 2022 | Humanis Saglık Anonim Sirketi |
| NCT03168555 | Phase 4 | Jun 1, 2017 | University of Copenhagen |
| NCT03059537 | Phase 4 | Mar 13, 2017 | University of Copenhagen |
| NCT02952963 | Phase 4 | Oct 1, 2016 | University of Copenhagen |
| NCT02876484 | Phase 4 | Jun 1, 2016 | University of Copenhagen |
| NCT02314208 | Phase 2 | Jan 1, 2015 | Institut National de la Santé Et de la Recherche Médicale, France, University of Paris |
| NCT02340247 | Phase 4 | Nov 1, 2014 | University of Copenhagen |
| NCT01666223 | N/A | Nov 1, 2012 | University of Copenhagen |
| NCT01674946 | Phase 1 | Sep 1, 2011 | University of Basel, University of Bern |
| NCT00912301 | Phase 2 | Apr 1, 2009 | Mayo Clinic, National Center for Research Resources (NCRR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| NCT00465751 | Early Phase 1 (Phase 1) | Oct 1, 2004 | Cantonal Hospital of St. Gallen, University of Bern |
| NCT00004442 | N/A | Oct 18, 1999 | University of Cincinnati |
| NCT00018694 | N/A | Oct 1, 1999 | Department of Veteran Affairs |
| NCT00004346 | Phase 2 | Jan 1, 1996 | National Center for Research Resources (NCRR), Oregon Health and Science University |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Copenhagen | Academic/Hospital | 6 | 6 | 2 | 2012 |
| National Center for Research Resources (NCRR) | Government | 2 | 1 | 1 | 1996 |
| University of Bern | Academic/Hospital | 2 | 2 | 1 | 2004 |
| Cantonal Hospital of St. Gallen | Academic/Hospital | 1 | 0 | 1 | 2004 |
| Department of Veteran Affairs | Government | 1 | 1 | 1 | 1999 |
| Humanis Saglık Anonim Sirketi | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Institut National de la Santé Et de la Recherche Médicale, France | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Leadiant Biosciences, Inc. | For profit | 1 | 1 | 1 | 2024 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Myungmoon Pharm. Co. | For profit | 1 | 1 | 1 | 2025 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 0 | 1 | 2009 |
| Oregon Health and Science University | Academic/Hospital | 1 | 0 | 1 | 1996 |
| University of Basel | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Cincinnati | Academic/Hospital | 1 | 1 | 1 | 1999 |
| University of Paris | Academic/Hospital | 1 | 0 | 1 | 2015 |
15 organizations
Page 1 / 1
Marketing (5)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| LGM Pharma | For profit | MKTG | Oct 22, 2009 |
| Leadiant Biosciences, Inc. | For profit | NDA2 | Jul 28, 1983 |
| Mirum Pharmaceuticals, Inc. | For profit | MKTG | Feb 21, 2025 |
| Nexgen Pharma, Inc | For profit | MKTG | Oct 22, 2009 |
| Rowell Laboratories | For profit | NDA | — |